Randomized phase <scp>III</scp> study of gemcitabine, cisplatin plus S‐1 versus gemcitabine, cisplatin for advanced biliary tract cancer (<scp>KHBO1401</scp>‐ <scp>MITSUBA</scp>)
Tatsuya Ioka(National Cancer Center Hospital East), Shogo Kobayashi(Osaka Gakuin University), Masashi Kanai(Kyoto University Hospital), Yoshitaro Shindo(Yamaguchi University), Takuma Goto(Asahikawa Medical University), Jiro Fujimoto(Hyogo Medical University), Daisuke Sakai(Stowers Institute for Medical Research), Masayuki Sho(Nara Medical University), Kenichi Yoshimura(Hiroshima University), Masanori Toyoda(Kobe University), Etsuro Hatano(Kyoto University), Hiroki Yamaue(Wakayama Medical University), Hidetoshi Eguchi(Osaka Gakuin University), Satoru Seo(Kōchi University), Hiroaki Nagano(Kyushu University), Akinobu Taketomi(Hokkaido University), Junzo Shimizu(Osaka Rosai Hospital), Hideo Baba(Kaketsuken (Japan)), Keiko Kamei(Kindai University Sakai Hospital), Masahiro Takahashi(Tohoku University Hospital), Tadatoshi Takayama(Nihon University)
Cited by 244
Related Papers
Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy
|Journal of Hepatology|2003|1.6k
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
|The Lancet Oncology|2015|1.1k
Trans-ancestry mutational landscape of hepatocellular carcinoma genomes
|Nature Genetics|2014|780
Prognostic Impact of Anatomic Resection for Hepatocellular Carcinoma
|Annals of Surgery|2005|641